DK1206457T3 - Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER - Google Patents

Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER

Info

Publication number
DK1206457T3
DK1206457T3 DK00959401T DK00959401T DK1206457T3 DK 1206457 T3 DK1206457 T3 DK 1206457T3 DK 00959401 T DK00959401 T DK 00959401T DK 00959401 T DK00959401 T DK 00959401T DK 1206457 T3 DK1206457 T3 DK 1206457T3
Authority
DK
Denmark
Prior art keywords
ppaps
biaryl
thia
oxa
modulators
Prior art date
Application number
DK00959401T
Other languages
Danish (da)
English (en)
Inventor
Dawn A Brooks
Christopher J Rito
Anthony J Shuker
Samuel J Dominianni
Alan M Warshawsky
Lynn S Gossett
Donald P Matthews
David A Hay
Robert J Ardecky
Pierre-Yves Michellys
John S Tyhonas
Original Assignee
Lilly Co Eli
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Ligand Pharm Inc filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1206457T3 publication Critical patent/DK1206457T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK00959401T 1999-08-27 2000-08-23 Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER DK1206457T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15116299P 1999-08-27 1999-08-27
PCT/US2000/023358 WO2001016120A1 (fr) 1999-08-27 2000-08-23 Derives de biaryl-oxa(thia)zole et leur utilisation en tant que modulateurs de ppar

Publications (1)

Publication Number Publication Date
DK1206457T3 true DK1206457T3 (da) 2004-02-16

Family

ID=22537578

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00959401T DK1206457T3 (da) 1999-08-27 2000-08-23 Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER

Country Status (13)

Country Link
US (3) US6417212B1 (fr)
EP (1) EP1206457B1 (fr)
JP (1) JP2003508389A (fr)
AR (1) AR025386A1 (fr)
AT (1) ATE252091T1 (fr)
AU (1) AU7073400A (fr)
CA (1) CA2382966A1 (fr)
DE (1) DE60005973T2 (fr)
DK (1) DK1206457T3 (fr)
ES (1) ES2204684T3 (fr)
PE (1) PE20010529A1 (fr)
PT (1) PT1206457E (fr)
WO (1) WO2001016120A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
EP1305017A4 (fr) * 2000-08-02 2004-01-14 Pharmanutrients Procedes et compositions pour la prevention et le traitement du syndrome x
EP1310494B1 (fr) * 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. ACTIVATEURS DE PPAR (delta)
ES2286137T3 (es) 2000-08-23 2007-12-01 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
ATE375985T1 (de) * 2000-08-23 2007-11-15 Lilly Co Eli Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
EA200400010A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов активаторов пролиферации пероксисом
EP1401434B1 (fr) * 2001-06-07 2006-11-15 Eli Lilly And Company Modulateurs des recepteurs actives par les proliferateurs du peroxisome (ppar)
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US20110065129A1 (en) 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
IL160304A0 (en) * 2001-08-10 2004-07-25 Nippon Chemiphar Co ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR delta
CA2460313C (fr) 2001-09-14 2011-03-08 Tularik Inc. Composes bisphenylsulfanyliques et bisphenylsulfonates et leur utilisation pour augmenter la teneur en cholesterol hdl
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EP1453811A2 (fr) 2001-11-30 2004-09-08 Eli Lilly And Company Agonistes du recepteur active de proliferation du peroxisome
AU2003214932A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
WO2003091211A1 (fr) * 2002-03-28 2003-11-06 Sumitomo Pharmaceuticals Co., Ltd. Composes d'heteroaryle
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
JP2005529975A (ja) 2002-06-19 2005-10-06 イーライ・リリー・アンド・カンパニー アミドリンカーペルオキシソーム増殖因子活性化受容体調節因子
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
WO2004063165A1 (fr) * 2003-01-06 2004-07-29 Eli Lilly And Company Derive de pyrazole utilise comme modulateur du recepteur ppar
US7319170B2 (en) * 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
CA2512883A1 (fr) 2003-02-14 2004-09-02 Eli Lilly And Company Derives de sulfonamides utilises comme modulateurs du recepteur ppar
EP1604971A4 (fr) * 2003-03-11 2006-08-16 Ono Pharmaceutical Co Procede permettant d'ajouter du charbon actif dans la purification d'eau et procede de purification d'eau
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
US7560475B2 (en) * 2003-09-22 2009-07-14 Ono Pharmaceutical Co., Ltd. Phenylacetic acid derivative, process for producing the same, and use
JP2007527416A (ja) 2003-10-31 2007-09-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）二重作動薬として有用なフェノキシ酢酸誘導体
JPWO2005095364A1 (ja) * 2004-03-30 2008-02-21 第一三共株式会社 フェノキシ酢酸誘導体及びそれを用いた医薬
CA2563461C (fr) 2004-04-28 2012-12-11 F. Hoffmann-La Roche Ag Derives de phenyl pyrazole utilises en tant qu'activateurs des ppar
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
WO2006018325A1 (fr) * 2004-08-17 2006-02-23 Galderma Research & Development, S.N.C. Nouveaux composes bioaromatiques activant les recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
FR2874378B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
KR20070047308A (ko) 2004-08-17 2007-05-04 갈데르마 리써어치 앤드 디벨로프먼트 Ｐｐａｒ 유형 수용체를 활성화시키는 신규 이방향족화합물, 및 미용 또는 약학적 조성물에서의 그의 용도
FR2874379B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
WO2006056752A1 (fr) 2004-11-23 2006-06-01 Astrazeneca Ab Derives d'acide phenoxyacetique utiles pour le traitement des maladies respiratoires
WO2007039736A1 (fr) 2005-10-06 2007-04-12 Astrazeneca Ab Nouveaux composes
TW200745003A (en) * 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US20080255150A1 (en) * 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
US20080293775A1 (en) * 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
US8023825B2 (en) * 2006-04-04 2011-09-20 Cisco Technology, Inc. Optical switching architectures for nodes in WDM mesh and ring networks
KR101507173B1 (ko) 2006-04-18 2015-03-30 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체 δ 의 활성화제
KR101130380B1 (ko) * 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
PT2277874T (pt) 2008-04-15 2018-08-10 Nippon Chemiphar Co Ativador para recetor ativado por proliferador de peroxissoma
NZ592603A (en) * 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
DK3065748T3 (da) 2014-12-23 2018-01-29 4D Pharma Res Ltd En bacteroides thetaiotaomicron stamme og dens anvendelse til reduktion af inflammation
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
AU2016278067B2 (en) 2015-06-15 2022-09-22 Cj Bioscience, Inc. Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3360559T (pt) 2015-06-15 2020-01-06 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
SG10201912326QA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB2561748B (en) 2015-11-20 2019-05-08 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR102010207B1 (ko) 2016-03-04 2019-08-12 4디 파마 피엘씨 세균 균주를 포함하는 조성물
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018215758A1 (fr) 2017-05-22 2018-11-29 4D Pharma Research Limited Compositions comprenant des souches bactériennes
WO2018215782A1 (fr) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprenant des souches bactériennes
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3804737T3 (pl) 2017-06-14 2022-09-12 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0635007A1 (fr) * 1992-04-10 1995-01-25 Smithkline Beecham Plc Composes heterocycliques et leur utilisation pour le traitement du diabete du type ii
US6048883A (en) 1992-07-03 2000-04-11 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (fr) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxoazoles et derives de pryridine destines a etre utilises pour le traitement du diabete tardif
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US6068976A (en) 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
JPH08325264A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−芳香環置換−３−フェニルプロピオン酸またはアクリル酸誘導体
JPH08325250A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
EP1426048A3 (fr) * 1995-09-18 2004-06-16 Ligand Pharmaceuticals, Inc. Traitement de l'hypertriglycéridémie avec un agoniste RXR en combinaison avec un agoniste PPARgamma
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
WO1997028115A1 (fr) * 1996-02-02 1997-08-07 Merck & Co., Inc. Agents anti-diabete
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
NZ334738A (en) 1996-08-19 2001-01-26 Japan Tobacco Inc Pyridinyl or oxazolyl substituted phenyl-propionic acid derivatives
EP1005344A4 (fr) * 1996-12-31 2003-03-19 Salk Inst For Biological Studi Traitement des liposarcomes par l'utilisation d'une association de thiazolidinediones et d'agonistes selectifs de recepteurs retino de x
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
WO1998043081A1 (fr) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Traitement de troubles gastro-intestinaux au moyen de modulateurs du recepteur active de la proliferation des peroxysomes (ppar)
ATE352561T1 (de) * 1997-05-30 2007-02-15 Dana Farber Cancer Inst Inc Pgc-1, ein neuartiger ppar-gamma-koaktivator aus braunem fettgewebe
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
US7098025B1 (en) * 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
WO1999020275A1 (fr) * 1997-10-17 1999-04-29 Aventis Pharmaceuticals Products Inc. Utilisations therapeutiques de derives de quinoline
WO1999019313A1 (fr) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant
WO1999029317A1 (fr) * 1997-12-12 1999-06-17 Purdue Research Foundation Methodes et compositions de traitement du diabete
ATE352545T1 (de) * 1997-12-19 2007-02-15 Merck & Co Inc Arylthiazolidindion-derivate
WO1999038850A1 (fr) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Nouveaux acides alcanoiques et leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant
JP4345230B2 (ja) * 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
GB2335597A (en) 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
WO1999051740A2 (fr) * 1998-04-06 1999-10-14 Janssen Pharmaceutica N.V. Sequence de nucleotides exprimant la proteine humaine de transport d'acides gras et sequence correspondante d'acides amines. utilisation pour reguler le metabolisme des acides gras
AR029876A1 (es) * 1998-05-11 2003-07-23 Takeda Pharmaceutical Compuesto de acido oxiiminoalcanoilo, composicion farmaceutica y agente para controlar receptores relacionados con retinoide que lo comprenden y su uso
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
PT1098639E (pt) * 1998-07-21 2005-06-30 Smithkline Beecham Plc A utilizacao de intensificadores de captacao da glicose para reduzir a apoptose
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
WO2001016120A9 (fr) 2002-07-11
AU7073400A (en) 2001-03-26
CA2382966A1 (fr) 2001-03-08
WO2001016120A1 (fr) 2001-03-08
EP1206457A1 (fr) 2002-05-22
US6417212B1 (en) 2002-07-09
DE60005973T2 (de) 2004-05-13
DE60005973D1 (de) 2003-11-20
ATE252091T1 (de) 2003-11-15
EP1206457B1 (fr) 2003-10-15
PE20010529A1 (es) 2001-05-18
JP2003508389A (ja) 2003-03-04
US20040019090A1 (en) 2004-01-29
PT1206457E (pt) 2004-03-31
US20030045558A1 (en) 2003-03-06
AR025386A1 (es) 2002-11-27
US6825222B2 (en) 2004-11-30
US6610696B2 (en) 2003-08-26
ES2204684T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
DK1206457T3 (da) Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
NO20021253L (no) Kinolylpropylpiperidinderivater og deres anvendelse som antibakterielle midler
DK1240164T3 (da) Benzazolderivater og deres anvendelse som JNK-modulatorer
DK1198454T3 (da) Multilinderivater og deres anvendelse som antibakterielle midler
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
CY2016002I2 (el) Ν-υποκατεστημενο καρβαμουλοξυαλκυλιο - παραγωγα αζολιου
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
NO20021400D0 (no) Terapeutiske konazolinderivater
EE04527B1 (et) Aromaatsed heterotsüklilised ühendid, nende kasutamine ja meetodid nende valmistamiseks
NO20020687D0 (no) 3(5)-ureidopyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
NO20012057L (no) 2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
AU5108000A (en) Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
NO20014603L (no) Tienopyrimidinforbindelser, deres fremstilling og anvendelse
NO20014702D0 (no) Diarylderivater og deres anvendelse som medikamenter
DK1218383T3 (da) Biocykliske imidazo-5-yl-aminoderivater
AUPQ309399A0 (en) Benzothiazoline derivatives
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO20001905L (no) (Poly)tiaalkynforbindelser og deres derivater, preparater omfattende disse og deres anvendelse
NO995513L (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-
NO20020155D0 (no) Aminotiazolderivater og deres anvendelse som CRF reseptorligander
DK1231211T3 (da) Thiazolidindion-derivater som antidiabetika
DK1173436T3 (da) Thiazolidindionderivat og anvendelse deraf som antidiabetikum
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DK1200409T3 (da) Substituerede isoquinolinderivater og deres anvendelse som krampestillende midler